Physician profile
Jonathan M Parker
NPI 1740232693
$2,915.43
in general payments reported to CMS, 2019-2025
32 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $653 · 2021: $286 · 2022: $485 · 2023: $561 · 2024: $416 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $792.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $290.31 | 2019-2025 | Farxiga |
| Abbvie INC. | $255.15 | 2020-2024 | |
| Lilly USA, LLC | $198.48 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $143.75 | 2022-2025 | |
| Abbott Laboratories | $137.77 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Glaxosmithkline, LLC. | $126.33 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.07 | 2023-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $108.46 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $63.78 | 2020-2021 | |
| Corium, LLC | $63.04 | 2022-2023 | Azstarys |
| Allergan, INC. | $57.41 | 2020 | |
| Axsome Therapeutics, INC. | $53.23 | 2025 | Symbravo |
| Currax Pharmaceuticals LLC | $47.02 | 2020-2023 | Contrave, Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $41.68 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $37.40 | 2020-2023 | |
| Genentech USA, INC. | $34.43 | 2019 | |
| Abiomed | $30.91 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.62 | 2023-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $30.44 | 2022 | |
| Merck Sharp & Dohme LLC | $27.28 | 2019-2021 | |
| Alfasigma USA, INC. | $27.28 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $27.09 | 2021 | |
| Averitas Pharma INC. | $26.18 | 2025 | Qutenza |
| Amarin Pharma, INC. | $23.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.27 | 2025 | Invega Sustenna |
| Antares Pharma, INC. | $19.01 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $18.68 | 2023 | Voquezna |
| Amgen INC. | $17.46 | 2025 | Evenity |
| Dexcom, INC. | $17.39 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.71 | 2024 | NP Thyroid 60 |
| Jazz Pharmaceuticals INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.